RSV Market Set for Robust Growth as Pipeline Advances
The Respiratory Syncytial Virus (RSV) market is expected to experience robust growth driven by innovation and pipeline advances, according to a DelveInsight report. The market size was valued at approximately USD 1,300 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034).
The market landscape is expected to be significantly shaped by therapies such as BEYFORTUS (nirsevimab), AREXVY (GSK3844766A) vaccine, and ABRYSVO (PF-06928316). Clover Biopharmaceuticals Ltd. recently announced positive preliminary Phase II results from a clinical trial conducted in older adults in Australia evaluating SCB-1022, a combination vaccine candidate targeting RSV and human metapneumovirus (hMPV), and SCB-1033, a three-component vaccine candidate targeting RSV, hMPV, and parainfluenza virus type 3 (PIV3).
Additionally, the U.S. FDA has accepted a supplemental Biologics License Application (sBLA) for Merck's Enflonsia (clesrovimab-cfor), seeking to expand its indication to prevent RSV lower respiratory tract disease (LRTD) in children younger than 2 years who remain at elevated risk of severe disease during their second RSV season.